Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 16, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company’s proprietary Targeted RNAi Molecule (TRiM™) platform.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
— Arrowhead to host R&D Day October 16, 2018 to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics PASADENA, Calif. --(BUSINESS WIRE)--Oct. 15, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical
View HTML
Toggle Summary Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 11, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on November 9-13, 2018 , in
View HTML
Toggle Summary Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen
- Upon closing, Arrowhead to receive $250 million , consisting of $175 million upfront payment from Janssen and $75 million equity investment from Johnson & Johnson Innovation – JJDC, Inc. - Arrowhead eligible to receive additional $3.5 billion in potential milestone payments, and potential further
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 25, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: The 14th Annual Meeting of the Oligonucleotide Therapeutics Society – Seattle , September 30-October 3, 2018 October 1
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 24, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIM TM ) platform on
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 21, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 14, 2018 , the Board of Directors approved "inducement" grants to nine new employees under Rule
View HTML
Toggle Summary Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists Summit
Data presented from the lowest two dose cohorts (100mg and 200mg ARO-HBV) Up to 4.0 log10 reduction in HBsAg observed following three doses of ARO-HBV ARO-HBV was generally well-tolerated in HBV patients PASADENA, Calif. --(BUSINESS WIRE)--Sep. 6, 2018-- Arrowhead Pharmaceuticals Inc.
View HTML
Toggle Summary Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 31, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 30, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: Annual B. Riley FBR Healthcare Conference – New York , September 4, 2018 Bruce Given , M.D., Arrowhead’s chief
View HTML